Background: A recent observational study among HIV-1 serodiscordant couples (uninfected women living with an infected partner) raised concerns about the safety of injectable contraceptives, especially depot medroxyprogesterone acetate (DMPA). The purpose of this paper is to assess the implications of potentially elevated risk of Human Immunodeficiency Virus (HIV) acquisition with the use of hormonal contraceptives for individual users and public policies. Study Design: Two indicators expressing costs (additional unwanted births and additional maternal deaths) in terms of the same unit of benefit (per 100 HIV infections averted) are estimated by using data on competing risks of unwanted birth and HIV acquisition associated with the use of various contraceptive methods. Elevated HIV acquisition risks associated with hormonal contraception observed in the observational studies of family planning users, sex workers and HIV-1 serodiscordant couples are used. Other relevant data for Kenya, South Africa and Zimbabwe are used to illustrate the potential effect of withdrawal of DMPA at the population level. Results: Both the risks of unwanted birth and HIV acquisition with sterilization, intrauterine devices (IUDs) and implants at the individual level are lower than those with DMPA. A shift from DMPA to an oral contraceptive (OC) or male condom by an individual could result in about 600 and a shift to no method in about 5400 additional unwanted births per 100 HIV infections averted. At the population level, the withdrawal of DMPA from Kenya, for example, could result in 7600 annual additional unwanted births and 40 annual additional maternal deaths per 100 HIV infections averted. Conclusion: Individual DMPA users may be advised to shift to sterilization, IUD or implant depending upon their reproductive needs and circumstances, but not to no method, OC or even condom alone. At the macro level, the decision to withdraw DMPA from family planning programs in sub-Saharan Africa is not warranted.
Introduction
A recent prospective observational study [1] among 1341 HIV-1 serodiscordant couples (uninfected women living with an infected partner) indicated that women using injectable contraception might be exposed to twice the risk of acquiring Human Immunodeficiency Virus (HIV) from their infected partners than those who used nonhormonal contraception. This study has raised concerns about the safety of injectable contraception, especially depot medroxyprogesterone acetate (DMPA). Some governments may even be contemplating to withdraw the DMPA injectable from their family planning programs. Is such an action warranted? Should women using DMPA be advised to shift to other methods? If so, which one? This paper addresses these issues by using information available about the competing risks of unwanted birth and HIV acquisition.
The strengths and weaknesses of previous observational studies on HIV acquisition risk associated with hormonal contraception have been reviewed by many researchers [2] [3] [4] [5] . The elevated HIV acquisition risk with hormonal contraception estimated in these studies may be an artifact of some of the methodological issues and behavioral factors, and to some extent may also reflect the biological effect of hormonal contraception. The proposed randomized trial(s) [4] may address some of the methodological issues involved in prior studies and may refine the magnitude of the risk involved. However, these randomized trials are unlikely to completely eliminate the effect of biases introduced by behavioral factors. Instead of waiting for the results of these trials, public discourse need to shift now to address the implications of the observational studies for the individual users and for public policies. This paper is an attempt in this direction. It assesses the implications of the estimated HIV acquisition risk for individual DMPA users and public policies by assuming as if the use of hormonal contraception would elevate the risk of HIV acquisition.
This analysis is guided by the principle that individuals would be interested in reducing their risk of having an unwanted birth as well as their risk of acquiring HIV. Similarly, the policy makers in a country would be interested in reducing the spread of HIV as well as reducing fertility and associated maternal mortality. Such an outcome may not be possible with DMPA if the elevated HIV risk with its use turns out to be real. The individuals may be faced with an unacceptable choice: whether to reduce their risk of having an unwanted birth but face an elevated risk of HIV acquisition by continuing with the DMPA or to face a higher risk of unwanted birth in order to reduce the risk of HIV acquisition by shifting away from the DMPA.
Methodology

Individual DMPA user
A shift from DMPA by an individual to another contraceptive method may involve some cost in terms of a higher risk of an unwanted birth and some benefit in terms of a lower risk of HIV acquisition, which could make the choice difficult. In order to guide the decision-making process by individual DMPA users, an index -additional unwanted births per 100 HIV infections averted -is proposed. This index can be used to compare various alternatives because it measures the magnitude of cost in terms of the same unit of benefit expected.
This index is estimated by using method-specific risks of birth and method-specific risks of HIV acquisition. The method-specific risks of birth are estimated by assuming that 30% of the method-specific pregnancies [6] associated with 1 year of use would be terminated by spontaneous or induced abortions ( Table 1 ). The number of additional unwanted births annually expected by shifting from DMPA to another method is estimated by subtracting the number of expected births with 1 year of DMPA use from the number of expected births with 1 year use of another method or no method.
Three scenarios for the elevated HIV acquisition risks associated with oral contraceptive (OC) and injectable (DMPA, Net-En) are created. These are based on the annual incidence rate among users of nonhormonal methods and adjusted hazard ratios for OC and injectable among family planning users [7, 8] , sex workers [9] and uninfected women living with an infected partner [1] . The annual incidence rates for OC and DMPA and Net-En users are estimated by multiplying these adjusted hazard ratios with the respective annual incidence rates among users of nonhormonal methods. The use of male and female condom is assumed to be 85% effective in preventing HIV infections. Other contraceptive methods [sterilization and intrauterine device (IUD)] are assumed to have the same HIV acquisition risk as users of nonhormonal methods ( Table 1) .
The number of HIV infections averted annually by shifting from DMPA to another method is estimated by subtracting the number of new HIV infections expected with 1 year of DMPA use from the number of new HIV infections expected with 1 year use of another method or no method. The numbers of unwanted births and new HIV infections expected among 100,000 women using a particular method or no method for 1 year are estimated by multiplying Table 1 Annual probabilities of pregnancy, birth and HIV acquisition by contraceptive method Contraceptive method Annual probability of pregnancy [6] Annual probability of birth Annual probability of HIV infection Family planning users [7, 8] Sex workers [9] Discordant couples [1] 100,000 and the annual probabilities of having a birth or HIV acquisition shown in Table 1 .
Policy options about DMPA
The effect of DMPA withdrawal is likely to be specific to the country context and will depend upon such factors as HIV prevalence and incidence rates among women 15-49 years of age, magnitude of HIV acquisition risk attributable to hormonal contraception, use of injectable, availability of other methods and what would injectable users do if DMPA is withdrawn. For comparison purposes, the current method mix among women 15-49 years of age in a country is taken as the baseline. The withdrawal of DMPA is also likely to affect the use of other brands of injectable. It is quite likely that some injectable users would stop using contraception altogether and some would shift to other available methods. To reflect this situation, it is assumed that injection users would shift to other available methods and no method in proportion to the current method mix in a country.
This shift would imply some cost -additional unwanted births and additional maternal deaths -as well as some benefit -fewer new HIV infections. The effect of DMPA withdrawal is assessed by using two indicators of costs-tobenefit ratios -additional unwanted births and additional maternal deaths per 100 HIV infections averted.
These indicators measure the magnitude of the cost in terms of the same unit of benefit derived; and thus, various alternatives can be compared. Their utility is illustrated for three countries in sub-Saharan Africa: Kenya, South Africa and Zimbabwe. The method-specific birth probabilities and HIV acquisition risks used in the individual-level analysis above are adjusted to reflect the context in each of these countries.
The method-specific birth probabilities are adjusted so that the number of births associated with the current method mix and the estimated number of women 15-49 years of age equal the projected number of births in that country. Similarly, the method-specific HIV incidence rates for family planning users, sex workers and discordant couples are adjusted so that the overall incidence rate associated with the current method mix equals the incidence rate for women 15-49 years of age in a country. The HIV incidence and prevalence rates for women 15-49 years of age are estimated from these rates for both sexes of the same age and by assuming that these rates for women are 60% higher than those for men (see Table 2 for relevant data for Kenya, South Africa and Zimbabwe used in the present analysis).
The expected number of births, maternal deaths and new HIV infections are then estimated by using the current method mix and the scenario for injection users described above. The number of additional unwanted births is estimated by subtracting the number of births associated with the assumed scenario from the number of births associated with the current method mix. Similarly, the number of additional maternal deaths and the number of HIV infections averted are estimated.
The effect of country context is assessed by comparing costs-to-benefit ratios among three countries; the effect of the magnitude of elevated HIV acquisition risks with hormonal contraception is assessed by comparing costs-tobenefit ratios among family planning users with those among sex workers and discordant couples. The costs-to-befit ratios are also estimated by varying the percent of injectable users who stop using contraception to demonstrate the effect of different assumptions about the behavior of injectable users.
Ethical consideration
No ethical approval for this study is required because it is based on data from published sources (Tables 1 and 2 ).
Results
Implications for individual DMPA user
It is assumed that individuals would be interested in minimizing both the risk of an unwanted birth and the risk of HIV acquisition. From this perspective, sterilization and nonhormonal IUDs are better than DMPA because both the risks of pregnancy and HIV acquisition with these methods are lower than the corresponding risks with DMPA (Table 1) . It is not known whether hormonal IUDs and implants would elevate the risk of HIV acquisition. If not, hormonal IUDs and implants would also be superior to DMPA.
However, the choice between DMPA and OC or condom or no method is not clear because the risk of unwanted birth associated with these alternatives is higher than that with DMPA, but the risk of HIV acquisition with these alternatives is lower than that with DMPA (Table 1) . This means that a shift from DMPA to OC or to condom or to no method would involve some cost -additional unwanted births -and some benefit -prevention of new HIV infections or HIV infections averted.
As shown in Table 1 , the use of DMPA is more effective than the use of condom, OC or no method in terms of unwanted births: about 59,500 out of 100,000 women are expected to give birth to a child if they do not use any contraceptive method for 1 year; this number reduces to 14,700 with 1-year use of female condom and 10,500 with 1-year use of male condom, to 5600 with 1-year use of OC and to 2100 with 1-year use of DMPA (obtained by multiplying annual probabilities in Table 1 by 100,000). A shift from DMPA to these alternatives would therefore result in additional unwanted births ranging from 3500 to 57,400 annually (panel 1, Table 3 ) [6] . The use of condom is most effective in terms of preventing new HIV infections. For example, about 2168 out of 100,000 family planning users would acquire HIV if they used condom for 1 year in comparison to 2550 if they did not use any method, 3035 if they used OC and 3621 if they used DMPA [1, [7] [8] [9] (obtained by multiplying annual probabilities in Table 1 by 100,000). The corresponding numbers of new HIV infections for discordant couples would be 3213, 3780, 6161 and 8278, respectively. Consequently, a shift from DMPA to any one of these alternatives would avert new HIV infections ranging from 587 to 1454 annually among family planning users, from 1775 to 5720 annually among sex workers and from 2117 to 5065 annually among discordant couples per year (panel 2, Table 3 ).
The estimated number of annual additional unwanted births per 100 HIV infections per year averted among family planning users would range from 597 with a shift to OC, 578 with a shift to male condom, 867 with a shift to female condom and 5359 with a shift to no method (panel 3, Table 3 ; Fig. 1 ). While the tip-off point would differ from individual to individual, these comparisons suggest that continuation with DMPA appears to be a better option than shifting to either no method or OC or even condom. This appears to be valid even for high-risk groups of sex workers and HIV-1 serodiscordant couples (uninfected women living with an infected partner). Recommending DMPA users to shift to condom alone would be less effective than recommending them to use condom in combination with DMPA or any other contraceptive method, especially if they can persuade their partners to use condom to reduce their risk of HIV acquisition.
Implications for public policy
The question is whether or not to withdraw DMPA from family planning programs. This policy issue is addressed within the context of three countries -Kenya, South Africa and Zimbabwe -with different levels of fertility, maternal mortality, use of DMPA and other injectables, and HIV prevalence and incidence rates ( Table 2 ). For example, South Africa has the lowest fertility and maternal mortality, but the highest HIV prevalence rate and use of injectable contraception. Kenya, on the other hand, has high fertility but low HIV prevalence rate, and Zimbabwe has the highest maternal mortality and the lowest use of injectable contraception. OC use is also highest in Zimbabwe. The percentage of women not using any method varies from 50% in South Africa to 72% in Kenya.
With the current method mix and adjusted probabilities of an unwanted birth, there were about 1.574 million annual births and 8342 annual maternal deaths in Kenya (column 1, panel 1, Table 4 ). These numbers would increase to 1.834 million annual births and 9722 maternal annual deaths if users of injectable contraception in Kenya shift to other methods (column 1, panel 2, Table 4 ). Under this scenario, the additional number of annual unwanted births would range between 28,729 in Zimbabwe and 363,335 in South Africa. Additional number of annual maternal deaths would range between 227 in Zimbabwe and 1490 in South Africa (panel 2, Table 4 ). Withdrawal of DMPA could decrease the overall annual HIV incidence rate among family planning users marginally: from 1.83% to 1.65% annually in South Africa and from 0.65% to 0.61% annually in Kenya (panels 1 and 3, Table 4 ). The number of new HIV infections among women 15-49 years of age under the current method mix in South Africa is estimated to be 194,963 per year (column 2, panel 1, Table 4 ; Fig. 2) . Similarly, additional annual maternal deaths per 100 HIV infections averted among family planning users would range from 8 in South Africa to 40 in Kenya annually (panel 3, Table 4 ; Fig. 3 ). These costs-to-benefit ratios for sex workers (panel 4, Table 4 ) and discordant couples (panel 5, Table 4 ) were slightly lower than those for family planning users (panel 3, Table 4 ). While HIV acquisition risks observed for high-risk group of women cannot be generalized to the low-risk group of family planning users, these costs-to-benefits ratios for all three groups in all three countries indicate that the decision to withdraw DMPA from the family planning program in these countries may not be warranted.
Sensitivity analysis
The above analysis was repeated for different percentage of injectable contraceptive users who would stop using contraception once DMPA is withdrawn from a country. The costs-to-benefit ratios in all three countries and for all three levels of HIV acquisition risks (family planning users, sex workers and discordant couples) increased with an increase in the proportion of injectable contraceptive users who stop using contraception altogether. For example, among family panning users in Kenya, additional annual unwanted births per 100 HIV infections averted increased from 2661 to 8868 annually and additional annual maternal deaths increased from 14 to 47 annually as the percentage of injectable users who stop using contraception increased from 25% to 100% (Table 5 ). The analysis for South Africa was also repeated by assuming that the elevated HIV acquisition risk associated with Net-En is the same as for users of nonhormonal contraception and that withdrawal of DMPA does not reduce the use of Net-En. These assumptions resulted in lower costs in terms of additional unwanted births and additional maternal deaths as well as lower benefit in terms of HIV infections averted. The costs-to-benefit ratios for family planning users in South Africa, however, were still favorable (1583 additional annual unwanted births and 6 additional annual maternal deaths per 100 HIV infections annually averted).
Discussion
While the elevated HIV acquisition risk with hormonal contraception estimated in previous studies may be an artifact of methodological and behavioral factors involved, the present analysis identified options for individual DMPA users and for public policies by assuming as if they were caused by the use of hormonal contraception. The present analysis estimated costs-(additional unwanted births and additional maternal deaths) to-benefit (HIV infections averted) ratios. While the acceptable cost-to-benefit ratio would depend upon the individual making the decision, these ratios can guide the decisions of an individual user, a health care provider and a program manager in a country.
The decision-making concerning whether to use a contraceptive method and which method to use is a complex process. Individuals consider many factors including their personal reproductive needs (whether to have the next child now, later or never), characteristics of a method, personal preferences and experiences, and availability and quality of contraceptive services. However, to make this choice manageable, we have considered two dimensions -the risk of an unwanted birth and the risk of HIV acquisitionassociated with 1-year use of various contraceptive methods. Furthermore, no matter how small the risk of an undesirable event -unwanted birth or HIV acquisition -with a contraceptive method, the outcome at the individual level is 1 or 0, i.e., either the individual DMPA user has the event or she does not. But in terms of selecting an option, one still has to consider the average risk of an event.
It is assumed that the individual user is interested in reducing both the risk of an unwanted birth and the risk of acquiring HIV. From this perspective, for the individual user, methods like sterilization, IUD and implant may be superior to the DMPA, but the DMPA appears to be better than no method, OC or even condom alone. The basic conclusion remains valid whether we use elevated HIV acquisition risks observed for family planning users, sex workers or those living with an infected partner. The application of the observed elevated HIV risks with hormonal contraception to data from Kenya, South Africa and Zimbabwe suggests that the decision to withdraw DMPA from family planning programs in these countries is not warranted because the cost of such a decision for family planning users would be high: 100 HIV infections averted annually would be equivalent to about 1902 additional unwanted births and 8 additional maternal deaths in South Africa, but 7566 additional unwanted births and 40 additional maternal deaths in Kenya. The magnitude of these costs-to-benefit ratios, however, would depend upon the levels of fertility, maternal mortality and HIV prevalence; the magnitude of HIV acquisition risk attributable to injectable use, the percentage of women using injectable contraception and the percentage of injectable users who would stop using a method once DMPA is withdrawn from a country. For example, these costs-to-benefit ratios for South Africa are low because of the relatively low fertility and low maternal mortality.
The present analysis has certain limitations. First, it did not incorporate female-to-male transmission. However, the conclusion is unlikely to change because the risks of female- 100  0  8868  2672  5407  47  11  43  75  25  6898  2080  4548  37  9  36  50  50  4832  1464  3494  26  6  28  25  75  2661  821  2206  14  3  17  0  100  379  152  550  2  1  4 to-male HIV transmission with hormonal contraception are lower than those of male-to-female HIV transmission [1] . Moreover, those men who are interested in reducing their risk of HIV acquisition ought to be modifying their sexual behavior and using condom effectively since they have the choice of partners in sexual relations and power to implement their choice. Second, this analysis did not include the potential elevated HIV risk due to pregnancy itself. However, the inclusion of this pregnancy-associated elevated risk of HIV acquisition would reduce the potential benefit in terms of HIV infections averted and therefore would further raise the costs-to-benefit ratios.
Third, the present analysis did not incorporate the effects of other factors such as unsafe abortions, neonatal mortality, Acquired Immune Deficiencies Syndrome (AIDs) mortality, Antiretroviral (ARV), various morbidities (maternal, neonatal, HIV and AIDs) and second-order effects of unwanted birth, maternal death and HIV infection on children, family and the society at large. It would be difficult to assess the implications of these factors on the results of this analysis because of the unavailability of comparative data to quantify these effects. However, some general speculative comments can be made. For example, the incorporation of neonatal mortality associated with maternal deaths would increase the cost and therefore the costs-to-benefit ratios. Similarly, the incorporation of maternal and neonatal morbidity would raise the costs-tobenefit ratios.
The present analysis assumed that 30% of pregnancies would be terminated by spontaneous and induced abortions. A higher percentage of induced abortions among unwanted pregnancies would result in lower number of unwanted births and lower number of associated maternal deaths. However, lack of availability for safe abortion services in a country would result in a higher number of maternal deaths associated with unsafe abortions. Most likely, the overall effect would be to lower the number of unwanted births per 100 HIV infections but to increase the number of maternal deaths per 100 HIV infections.
The present analysis measured benefit in terms of HIV infections averted because it would avert subsequent HIVand AIDs-related morbidity and AIDs-related mortality among these women. This potential benefit is likely to decrease with the increase in the availability and use of ARV, which would imply that most of the HIV-infected women would be able to manage their disease, spend a long productive life and reduce AIDs-related mortality.
The present analysis used data on HIV acquisition risk with hormonal contraception from three prospective observational studies [1, [7] [8] [9] , which have many strengths but also suffer from various methodological issues [2] [3] [4] [5] . Furthermore, while the HIV acquisition risks (observed and adjusted) with OC and DMPA were statistically significant for sex workers [9] , the HIV acquisition risk with OC was statistically significant neither for family planning users nor for discordant couples [1, 7, 8] . Neither were the observed HIV acquisition risks with injectable contraceptives. The hazard ratio measuring the HIV acquisition risk became significant marginally for discordant couples with p values of .04 and .05 only after statistical adjustments [1] . This hazard ratio for family planning users was not significant after adjustments were made through Cox proportional hazard model [7] , but it became significant marginally with p value of .04 only after adjusting through marginal structural model analysis [8] . These observations suggest that there may be a variable that negatively confounded the relationship between HIV acquisition risk and injectable use. None of these studies, however, identified this confounder that raised the magnitude of the hazard ratio with injectable and changed its significance after adjustment. It is possible that a higher proportion of those women who believed themselves to be at a high HIV acquisition risk were already using condom and using it more effectively than others. Perhaps, this issue can be addressed by estimating HIV acquisition risks with hormonal and nonhormonal methods separately for users and nonusers of condom or for those with protected and unprotected sex. Furthermore, the absence of statistically significant relationship between OC use and HIV acquisition among family planning users and discordant couples may imply that, in addition to the small number of OC users, either the exposure to OC use was not collected adequately or estrogen provided some protection against HIV acquisition.
The issue -whether or not the use of hormonal contraception actually elevates HIV acquisition risk -is unlikely to be resolved by behavioral studies alone. We need to establish biological mechanisms involved with the use of a specific hormone, its dosage and the route of administration.
While a randomized trial has been suggested [4] to provide a definite answer, such a trial may not be ethical and is unlikely to be feasible [1, 7] . In order to be enrolled in such a trial, women would have to be equally interested in reducing their risk of pregnancy as well as their risk of HIV acquisition. Offering choice of appropriate method to reduce the likelihood of an unwanted pregnancy is one of the basic principles imbedded in the plan of action [15] emerging from the 1994 International Conference on Population and Development. Moreover, the selection of a method depends upon personal reproductive needs (whether and when to have the next child: now, later or never), characteristics of methods, preferences and experiences, and availability and quality of services. It may be unethical to assign women even with the same reproductive needs to a specific method irrespective of their preferences and experiences. The study would not be feasible because of high rates of switching among methods, especially if the method initially assigned does not match the preferences of the client. Moreover, the effect of bias due to the differences in protective behaviors among women who may believe themselves to be at a high risk of HIV acquisition may be difficult to eliminate completely.
Such a randomized trial, perhaps, may not even be needed in view of the analysis presented in this paper, which assumes that the use of hormonal contraception actually elevates the risk of HIV acquisition. The results of any such simulation are likely to be context-specific, and it would be important to repeat it for other countries with different context. However, the basic conclusion is unlikely to change because the present analysis included three countries with very different contexts. South Africa has one of the lowest fertility and maternal mortality but high HIV prevalence. As shown by the results for Kenya and Zimbabwe, the costs-to-benefit ratio for countries with higher fertility, higher maternal mortality and lower HIV prevalence than South Africa would be even higher that those observed in this study.
Conclusions
Individual DMPA users may be advised to shift to sterilization, IUD or implant provided that these methods match their reproductive needs and circumstance, but not to OC, no method or even condom alone. At the macro level, the decision to withdraw DMPA from family planning programs is not warranted.
